Oncology Central

Second line in NSCLC: new opportunities?

0

Every patient affected by advanced and recurrent NSCLC, despite modest outcome benefits from first-line therapy, experiences disease progression and requires salvage therapy. In second-line settings, only a small percentage of patients, in other words, those with oncogene-addicted NSCLC, can benefit from specific inhibitors if still not received at first line, and another small percentage may be enrolled in clinical trials.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.

Share:

Insights

Videos

News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.